Several possible studies
Story checked
How hATTR-CM Differs for Black Patients (opens in a new tab)
webmd.com · 2026-05-26
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
How hATTR-CM Differs for Black Patients
webmd.com · 2026-05-26
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 3 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Cited as backgroundpresented as earlier work
Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis
- Cited as backgroundpresented as earlier work
Geographic Healthcare Disparities and Diagnostic Trends Among Patients with Transthyretin Amyloid Cardiomyopathy
- Cited as backgroundpresented as the new finding
Validation Of The Transthyretin Amyloidosis Cardiomyopathy Score In A Black And Hispanic Screening Population: An Interim Analysis Of The First 342 Cases From The SCAN-MP Study
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedHereditary ATTR-CM is more common in people of West African descent, and about 4% of Black Americans carry the V122I mutation.View evidenceHide evidence
As statedabout 4%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedBlack people are more likely to be diagnosed with advanced ATTR-CM, and the article says this may reflect underdiagnosis or misdiagnosis rather than greater biologic vulnerability.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedA study in JAMA Cardiology found that Southern states, where most Black Americans live, have the lowest percentage of ATTR-CM diagnoses.View evidenceHide evidence
As statedlowest percentage
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedA study in the Journal of the American College of Cardiology found that patients in the Southeast travel around 75 miles to an amyloid center on average, compared with about 30 miles in the Northeast.View evidenceHide evidence
As statedaround 75 miles vs about 30 miles
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedBlack patients have less access to ATTR-CM drugs, in part because the medications can cost about $244,000 to nearly $500,000 per year.View evidenceHide evidence
As statedabout $244,000 to nearly $500,000 a year
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedMost clinical trial participants in ATTR-CM studies are White, and the article says Black patients have not always been specifically recruited.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe SCAN-MP study is screening and diagnosing Black patients over age 60 with signs of heart failure using special heart scans, with the hope of identifying people with the mutation before symptoms appear.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
INSIGHT Model: Explainable Artificial Intelligence for Real-World EHR-Based Screening of Transthyretin Amyloidosis Cardiomyopathy.
JACC. Advances · 2026 · PubMed
Nuclear imaging in transthyretin amyloid cardiomyopathy
Crossref
Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non-amyloid Heart Failure and the General Population.
Journal of the American Heart Association · 2026 · PubMed, Europe PMC
Artificial intelligence in cardiology: implications for healthcare outcomes.
Frontiers in Artificial Intelligence · 2026 · PubMed
A Machine Learning Approach for Early Diagnosis of Transthyretin Amyloid Cardiomyopathy Among Heart Failure Patients
Crossref
And 10 more candidates considered.